New pill shows promise against rare bile duct cancer in Late-Stage trial
Disease control
Not yet recruiting
This study tests a new oral drug, TT-00420, against standard chemotherapy for people with advanced bile duct cancer that has a specific genetic change (FGFR2). The trial includes 138 adults whose cancer worsened after initial treatment. The goal is to see if the new drug can slow…
Phase: PHASE3 • Sponsor: TransThera Sciences (Nanjing), Inc. • Aim: Disease control
Last updated May 15, 2026 11:54 UTC